Point-of-care measurements of platelet inhibition after clopidogrel loading in patients with acute coronary syndrome: comparison of generic and branded clopidogrel bisulfate. 
Platelet-function suppression with antiplatelet therapy is effective in preventing and treating cardiovascular disease.  Clopidogrel is a thienopyridine derivative that blocks platelet activation by adenosine diphosphate receptor binding.  This study demonstrates the effects of generic clopidogrel bisulfate in comparison to branded clopidogrel bisulfate in patients with acute coronary syndromes.  This prospective, 2-arm, single-center, open-label trial used 1:1 randomization to assign patients to receive generic or branded clopidogrel bisulfate.  Patients with unstable angina or non-ST-segment elevation myocardial infarction and scheduled to undergo coronary angiography were enrolled.  Platelet function was measured with a P2Y12 assay and reported in P2Y12 reaction units (PRU) and aspirin reaction units (ARU) after randomization.  Platelet function was measured at 2, 4, 8, and 24 hours after 600-mg clopidogrel loading.  The clinical outcome was checked at 1 month after coronary angiography.  Ninety-five patients were enrolled and randomized to the generic or branded group.  Ninety patients (62 men [69%], 28 women [31%]; mean age, 58 years) completed the study protocol.  The clinical characteristics were similar between the 2 groups.  The difference in the baseline PRU measurements between the generic and branded groups was not significant (274.8 [59.7] vs 285.4 [62.4], respectively; P = 0.414).  There were significant differences in 2-hour PRU (231.1 [71.3] vs 266.9 [67.4]; P = 0.017) and 4-hour PRU (227.3 [80.4] vs 265.7 [71.0]; P = 0.020); however, 24-hour PRU (200.5 [82.1] vs 220.6 [75.8]; P = 0.253) was similar.  No death, myocardial infarction, target lesion revascularization, stent thrombosis, or Thrombolysis in Myocardial Infarction-defined major bleeding complications were reported during in-hospital stay or 1-month follow-up.  In patients with ACS, loading of generic clopidogrel bisulfate was associated with an antiplatelet effect comparable to that of branded clopidogrel bisulfate.  ClinicalTrials.gov identifier: NCT02060786.